FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164083401> ?p ?o ?g. }

• W2164083401 endingPage "1078" @default.
• W2164083401 startingPage "1072" @default.
• W2164083401 abstract "There is currently no effective treatment for Friedreich's ataxia (FA), the most common of the hereditary ataxias. The disease is caused by mutations in FRDA that drastically reduce expression levels of the mitochondrial protein frataxin. In FA animal models, a key difficulty is obtaining the precise levels of frataxin expression in the appropriate tissues to provoke pathology without early lethality. To develop strategies to circumvent these problems, conditional frataxin transgenic mice have been generated. We now show that frataxin expression can be eliminated in neurons from these loxP[frda] mice by infection with CRE-expressing herpes simplex virus type 1 (HSV-1) amplicon vectors. We have also achieved in vivo delivery by stereotaxic injection of these CRE-expressing vectors into the brainstem of loxP[frda] mice to generate a localized gene knockout model. These mice develop a behavioral deficit in the rotarod assay detectable after 4 weeks, and when re-injected with HSV-1 amplicon vectors expressing human frataxin complementary DNA (cDNA) exhibit behavioral recovery as early as 4 weeks after the second injection. To the best of our knowledge, this is the first proof of principle of recovery of neurological function by a therapeutic agent aimed at correcting frataxin deficiency. There is currently no effective treatment for Friedreich's ataxia (FA), the most common of the hereditary ataxias. The disease is caused by mutations in FRDA that drastically reduce expression levels of the mitochondrial protein frataxin. In FA animal models, a key difficulty is obtaining the precise levels of frataxin expression in the appropriate tissues to provoke pathology without early lethality. To develop strategies to circumvent these problems, conditional frataxin transgenic mice have been generated. We now show that frataxin expression can be eliminated in neurons from these loxP[frda] mice by infection with CRE-expressing herpes simplex virus type 1 (HSV-1) amplicon vectors. We have also achieved in vivo delivery by stereotaxic injection of these CRE-expressing vectors into the brainstem of loxP[frda] mice to generate a localized gene knockout model. These mice develop a behavioral deficit in the rotarod assay detectable after 4 weeks, and when re-injected with HSV-1 amplicon vectors expressing human frataxin complementary DNA (cDNA) exhibit behavioral recovery as early as 4 weeks after the second injection. To the best of our knowledge, this is the first proof of principle of recovery of neurological function by a therapeutic agent aimed at correcting frataxin deficiency." @default.
• W2164083401 created "2016-06-24" @default.
• W2164083401 creator A5028348408 @default.
• W2164083401 creator A5031041314 @default.
• W2164083401 creator A5047620994 @default.
• W2164083401 creator A5079037946 @default.
• W2164083401 creator A5084027100 @default.
• W2164083401 creator A5084519901 @default.
• W2164083401 creator A5087630921 @default.
• W2164083401 date "2007-06-01" @default.
• W2164083401 modified "2023-10-18" @default.
• W2164083401 title "Functional Recovery in a Friedreich's Ataxia Mouse Model by Frataxin Gene Transfer Using an HSV-1 Amplicon Vector" @default.
• W2164083401 cites W1484379620 @default.
• W2164083401 cites W1489266920 @default.
• W2164083401 cites W1533387942 @default.
• W2164083401 cites W1583371287 @default.
• W2164083401 cites W1583466448 @default.
• W2164083401 cites W1598292644 @default.
• W2164083401 cites W1669028609 @default.
• W2164083401 cites W1964340993 @default.
• W2164083401 cites W1966828804 @default.
• W2164083401 cites W1972784372 @default.
• W2164083401 cites W1977947450 @default.
• W2164083401 cites W1980545988 @default.
• W2164083401 cites W1984080741 @default.
• W2164083401 cites W1999185549 @default.
• W2164083401 cites W2004049878 @default.
• W2164083401 cites W2011759409 @default.
• W2164083401 cites W2014020549 @default.
• W2164083401 cites W2021734722 @default.
• W2164083401 cites W2029101208 @default.
• W2164083401 cites W2031653245 @default.
• W2164083401 cites W2052430755 @default.
• W2164083401 cites W2052736131 @default.
• W2164083401 cites W2055876297 @default.
• W2164083401 cites W2057197938 @default.
• W2164083401 cites W2078532772 @default.
• W2164083401 cites W2086302260 @default.
• W2164083401 cites W2107851792 @default.
• W2164083401 cites W2110864849 @default.
• W2164083401 cites W2139592965 @default.
• W2164083401 cites W2151669000 @default.
• W2164083401 cites W2158155007 @default.
• W2164083401 cites W2168359248 @default.
• W2164083401 cites W69038043 @default.
• W2164083401 doi "https://doi.org/10.1038/sj.mt.6300143" @default.
• W2164083401 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17375064" @default.
• W2164083401 hasPublicationYear "2007" @default.
• W2164083401 type Work @default.
• W2164083401 sameAs 2164083401 @default.
• W2164083401 citedByCount "52" @default.
• W2164083401 countsByYear W21640834012012 @default.
• W2164083401 countsByYear W21640834012013 @default.
• W2164083401 countsByYear W21640834012014 @default.
• W2164083401 countsByYear W21640834012015 @default.
• W2164083401 countsByYear W21640834012016 @default.
• W2164083401 countsByYear W21640834012017 @default.
• W2164083401 countsByYear W21640834012019 @default.
• W2164083401 countsByYear W21640834012020 @default.
• W2164083401 countsByYear W21640834012021 @default.
• W2164083401 countsByYear W21640834012022 @default.
• W2164083401 countsByYear W21640834012023 @default.
• W2164083401 crossrefType "journal-article" @default.
• W2164083401 hasAuthorship W2164083401A5028348408 @default.
• W2164083401 hasAuthorship W2164083401A5031041314 @default.
• W2164083401 hasAuthorship W2164083401A5047620994 @default.
• W2164083401 hasAuthorship W2164083401A5079037946 @default.
• W2164083401 hasAuthorship W2164083401A5084027100 @default.
• W2164083401 hasAuthorship W2164083401A5084519901 @default.
• W2164083401 hasAuthorship W2164083401A5087630921 @default.
• W2164083401 hasBestOaLocation W21640834011 @default.
• W2164083401 hasConcept C102230213 @default.
• W2164083401 hasConcept C104317684 @default.
• W2164083401 hasConcept C111599444 @default.
• W2164083401 hasConcept C169760540 @default.
• W2164083401 hasConcept C2779314966 @default.
• W2164083401 hasConcept C2779369046 @default.
• W2164083401 hasConcept C2780906641 @default.
• W2164083401 hasConcept C40767141 @default.
• W2164083401 hasConcept C49105822 @default.
• W2164083401 hasConcept C54355233 @default.
• W2164083401 hasConcept C8185291 @default.
• W2164083401 hasConcept C86803240 @default.
• W2164083401 hasConcept C92087593 @default.
• W2164083401 hasConceptScore W2164083401C102230213 @default.
• W2164083401 hasConceptScore W2164083401C104317684 @default.
• W2164083401 hasConceptScore W2164083401C111599444 @default.
• W2164083401 hasConceptScore W2164083401C169760540 @default.
• W2164083401 hasConceptScore W2164083401C2779314966 @default.
• W2164083401 hasConceptScore W2164083401C2779369046 @default.
• W2164083401 hasConceptScore W2164083401C2780906641 @default.
• W2164083401 hasConceptScore W2164083401C40767141 @default.
• W2164083401 hasConceptScore W2164083401C49105822 @default.
• W2164083401 hasConceptScore W2164083401C54355233 @default.
• W2164083401 hasConceptScore W2164083401C8185291 @default.
• W2164083401 hasConceptScore W2164083401C86803240 @default.
• W2164083401 hasConceptScore W2164083401C92087593 @default.
• W2164083401 hasIssue "6" @default.

• next